Literature DB >> 17307308

Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells.

Xianmin Bu1, Zhiyong Zheng, Chen Wang, Yinghao Yu.   

Abstract

We evaluated the deposition of C4d in follicular lymphomas (FL) and extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma). Deposition of C4d was detected in 118 lymphoma tissues from patients with lymphoma and in 20 reactive hyperplasia lymphadens (RHL) using immunohistochemistical methods. FL, MALT lymphoma, and RHL were studied using double staining for CD35/C4d and Bcl-2/C4d. We studied 26 FL tissues, 19 of which showed C4d deposition. C4d deposition was detected around the follicular dendritic cells (FDCs) in the neoplastic follicles. There was no significant difference between the positive ratio of C4d and the grades of FL. We studied 12 MALT lymphoma tissues, six of which displayed C4d deposition. In these tissues, C4d deposition was detected in the peripheral region of partially colonized follicles in the form of an irregular ring, but was not found in the central region. C4d deposition was negative in completely colonized follicles. There was no C4d deposition in diffuse large B-cell lymphomas, mantle cell lymphomas, B-small lymphocytic lymphomas, T-lymphoblastic lymphomas, peripheral T-cell lymphomas, and anaplastic large cell lymphomas. C4d around the FDCs in the neoplastic follicles was a specific indicator for FL. C4d deposition in partially colonized follicles of MALT lymphoma was completely different from that in neoplastic follicles of FL, forming a key point for differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307308     DOI: 10.1016/j.prp.2006.11.004

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay.

Authors:  Omar Massoud; Julie Heimbach; Kimberly Viker; Anuradha Krishnan; John Poterucha; William Sanchez; Kymberly Watt; Russell Wiesner; Michael Charlton
Journal:  Liver Transpl       Date:  2011-06       Impact factor: 5.799

Review 2.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 3.  Complement and macrophage crosstalk during process of angiogenesis in tumor progression.

Authors:  M Afzal Khan; A M Assiri; D C Broering
Journal:  J Biomed Sci       Date:  2015-07-22       Impact factor: 8.410

4.  Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.

Authors:  Thomas Klikovits; Paul Stockhammer; Viktoria Laszlo; Yawen Dong; Mir Alireza Hoda; Bahil Ghanim; Isabelle Opitz; Thomas Frauenfelder; Thi Dan Linh Nguyen-Kim; Walter Weder; Walter Berger; Michael Grusch; Clemens Aigner; Walter Klepetko; Balazs Dome; Ferenc Renyi-Vamos; Rudolf Oehler; Balazs Hegedus
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

Review 5.  Complement in Metastasis: A Comp in the Camp.

Authors:  Daniel Ajona; Sergio Ortiz-Espinosa; Ruben Pio; Fernando Lecanda
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

6.  Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.

Authors:  P Riihilä; K Viiklepp; L Nissinen; M Farshchian; M Kallajoki; A Kivisaari; S Meri; J Peltonen; S Peltonen; V-M Kähäri
Journal:  Br J Dermatol       Date:  2019-07-28       Impact factor: 9.302

7.  Complement activation in astrocytomas: deposition of C4d and patient outcome.

Authors:  Katri Mäkelä; Pauli Helén; Hannu Haapasalo; Timo Paavonen
Journal:  BMC Cancer       Date:  2012-12-01       Impact factor: 4.430

Review 8.  Complement inhibition in cancer therapy.

Authors:  Ruben Pio; Daniel Ajona; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-24       Impact factor: 10.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.